Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes.

Piovan C, Marin V, Scavullo C, Corna S, Giuliani E, Bossi S, Galy A, Fenard D, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2017 Mar 8;5:22-30. doi: 10.1016/j.omtm.2017.02.003. eCollection 2017 Jun 16.

2.

Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.

Zucchelli E, Pema M, Stornaiuolo A, Piovan C, Scavullo C, Giuliani E, Bossi S, Corna S, Asperti C, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2017 Jan 11;4:102-114. doi: 10.1016/j.omtm.2017.01.002. eCollection 2017 Mar 17.

3.

Determination of Interference During In Vitro Pyrogen Detection: Development and Characterization of a Cell-Based Assay.

Palma L, Rossetti F, Dominici S, Buondelmonte C, Rocchi MB, Rizzardi GP, Vallanti G, Magnani M.

Assay Drug Dev Technol. 2017 Feb/Mar;15(2):64-76. doi: 10.1089/adt.2016.758. Epub 2016 Dec 20.

PMID:
27996302
4.

RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope.

Marin V, Stornaiuolo A, Piovan C, Corna S, Bossi S, Pema M, Giuliani E, Scavullo C, Zucchelli E, Bordignon C, Rizzardi GP, Bovolenta C.

Mol Ther Methods Clin Dev. 2016 May 11;3:16033. doi: 10.1038/mtm.2016.33. eCollection 2016.

5.

The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.

Porcellini S, Asperti C, Valentinis B, Tiziano E, Mangia P, Bordignon C, Rizzardi GP, Traversari C.

Oncoimmunology. 2015 Jul 1;4(10):e1041700. eCollection 2015 Oct.

6.

Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF.

Di Matteo P, Mangia P, Tiziano E, Valentinis B, Porcellini S, Doglioni C, Sanvito F, Bordignon C, Rizzardi GP, Traversari C.

Clin Exp Metastasis. 2015 Mar;32(3):289-300. doi: 10.1007/s10585-015-9704-7. Epub 2015 Feb 4.

PMID:
25648442
7.

NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells.

Di Matteo P, Hackl C, Jedeszko C, Valentinis B, Bordignon C, Traversari C, Kerbel RS, Rizzardi GP.

Br J Cancer. 2013 Jul 23;109(2):360-9. doi: 10.1038/bjc.2013.347. Epub 2013 Jul 4.

8.

RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy.

Stornaiuolo A, Piovani BM, Bossi S, Zucchelli E, Corna S, Salvatori F, Mavilio F, Bordignon C, Rizzardi GP, Bovolenta C.

Hum Gene Ther Methods. 2013 Aug;24(4):228-40. doi: 10.1089/hgtb.2012.190. Epub 2013 Aug 3.

9.

De novo design of a tumor-penetrating peptide.

Alberici L, Roth L, Sugahara KN, Agemy L, Kotamraju VR, Teesalu T, Bordignon C, Traversari C, Rizzardi GP, Ruoslahti E.

Cancer Res. 2013 Jan 15;73(2):804-12. doi: 10.1158/0008-5472.CAN-12-1668. Epub 2012 Nov 14.

10.

Molecular dynamics reveal that isoDGR-containing cyclopeptides are true αvβ3 antagonists unable to promote integrin allostery and activation.

Ghitti M, Spitaleri A, Valentinis B, Mari S, Asperti C, Traversari C, Rizzardi GP, Musco G.

Angew Chem Int Ed Engl. 2012 Jul 27;51(31):7702-5. doi: 10.1002/anie.201202032. Epub 2012 Jun 20.

PMID:
22718573
11.

Enhanced expression of CD13 in vessels of inflammatory and neoplastic tissues.

Di Matteo P, Arrigoni GL, Alberici L, Corti A, Gallo-Stampino C, Traversari C, Doglioni C, Rizzardi GP.

J Histochem Cytochem. 2011 Jan;59(1):47-59. doi: 10.1369/jhc.2010.956644.

12.

Use of metadynamics in the design of isoDGR-based αvβ3 antagonists to fine-tune the conformational ensemble.

Spitaleri A, Ghitti M, Mari S, Alberici L, Traversari C, Rizzardi GP, Musco G.

Angew Chem Int Ed Engl. 2011 Feb 18;50(8):1832-6. doi: 10.1002/anie.201007091. Epub 2011 Jan 18. No abstract available.

PMID:
21328650
13.

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.

Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C.

Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12.

PMID:
20708923
14.

Chim3 confers survival advantage to CD4+ T cells upon HIV-1 infection by preventing HIV-1 DNA integration and HIV-1-induced G2 cell-cycle delay.

Porcellini S, Gubinelli F, Alberici L, Piovani BM, Rizzardi GP, Bovolenta C.

Blood. 2010 May 20;115(20):4021-9. doi: 10.1182/blood-2009-09-243030. Epub 2010 Mar 10.

15.

Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.

Curnis F, Cattaneo A, Longhi R, Sacchi A, Gasparri AM, Pastorino F, Di Matteo P, Traversari C, Bachi A, Ponzoni M, Rizzardi GP, Corti A.

J Biol Chem. 2010 Mar 19;285(12):9114-23. doi: 10.1074/jbc.M109.044297. Epub 2010 Jan 11.

16.

2D TR-NOESY experiments interrogate and rank ligand-receptor interactions in living human cancer cells.

Mari S, Invernizzi C, Spitaleri A, Alberici L, Ghitti M, Bordignon C, Traversari C, Rizzardi GP, Musco G.

Angew Chem Int Ed Engl. 2010 Feb 1;49(6):1071-4. doi: 10.1002/anie.200905941. No abstract available.

PMID:
20058288
17.

NGR and isoDGR are separate moieties binding to different receptors.

Rizzardi GP, Bordignon C.

Blood. 2009 May 21;113(21):5366; author reply 5367. doi: 10.1182/blood-2009-02-207068. No abstract available.

18.

The F12-Vif derivative Chim3 inhibits HIV-1 replication in CD4+ T lymphocytes and CD34+-derived macrophages by blocking HIV-1 DNA integration.

Porcellini S, Alberici L, Gubinelli F, Lupo R, Olgiati C, Rizzardi GP, Bovolenta C.

Blood. 2009 Apr 9;113(15):3443-52. doi: 10.1182/blood-2008-06-158790. Epub 2009 Feb 11.

19.

Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNgamma.

Gasparri AM, Jachetti E, Colombo B, Sacchi A, Curnis F, Rizzardi GP, Traversari C, Bellone M, Corti A.

Mol Cancer Ther. 2008 Dec;7(12):3859-66. doi: 10.1158/1535-7163.MCT-08-0538.

20.

Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif.

Curnis F, Sacchi A, Gasparri A, Longhi R, Bachi A, Doglioni C, Bordignon C, Traversari C, Rizzardi GP, Corti A.

Cancer Res. 2008 Sep 1;68(17):7073-82. doi: 10.1158/0008-5472.CAN-08-1272.

Supplemental Content

Loading ...
Support Center